The management of schizophrenia: focus on extended-release quetiapine fumarate

Joseph Peuskens Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Kortenberg, Belgium Abstract: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Peuskens J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0a7a9e29149b401290c9eac1d3864aa3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0a7a9e29149b401290c9eac1d3864aa3
record_format	dspace
spelling	oai:doaj.org-article:0a7a9e29149b401290c9eac1d3864aa32021-12-02T08:19:25ZThe management of schizophrenia: focus on extended-release quetiapine fumarate1176-63281178-2021https://doaj.org/article/0a7a9e29149b401290c9eac1d3864aa32011-09-01T00:00:00Zhttp://www.dovepress.com/the-management-of-schizophrenia-focus-on-extended-release-quetiapine-f-a8324https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Joseph Peuskens Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Kortenberg, Belgium Abstract: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention. Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability profile in schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers a simplified dosing regimen and titration schedule. Short-term clinical studies have shown that quetiapine XR (400&ndash;800 mg/d) is efficacious in the acute treatment of schizophrenia, while a long-term study has shown that quetiapine XR was significantly more effective than placebo at preventing relapse. Furthermore, an investigation in which stable patients switched from the immediate-release formulation (quetiapine IR) to quetiapine XR showed that quetiapine XR is generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment. In conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. Furthermore, once-daily dosing may improve patient adherence, which may impact positively on patient outcomes. Keywords: adherence, atypical antipsychotics, adverse eventsPeuskens JDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 549-564 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Peuskens J The management of schizophrenia: focus on extended-release quetiapine fumarate
description	Joseph Peuskens Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Kortenberg, Belgium Abstract: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there remains an opportunity to further improve symptom control and long-term relapse prevention. Also, a number of factors, including tolerability and complex dosing regimens, can result in nonadherence to medication. Quetiapine is an atypical antipsychotic with proven efficacy and an established tolerability profile in schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers a simplified dosing regimen and titration schedule. Short-term clinical studies have shown that quetiapine XR (400&ndash;800 mg/d) is efficacious in the acute treatment of schizophrenia, while a long-term study has shown that quetiapine XR was significantly more effective than placebo at preventing relapse. Furthermore, an investigation in which stable patients switched from the immediate-release formulation (quetiapine IR) to quetiapine XR showed that quetiapine XR is generally well tolerated and has no loss of efficacy compared with quetiapine IR. In patients who experienced insufficient efficacy or poor tolerability on their previous antipsychotic, switching to quetiapine XR significantly improved efficacy compared with the previous treatment. In conclusion, quetiapine XR is an effective and generally well tolerated treatment for schizophrenia. Furthermore, once-daily dosing may improve patient adherence, which may impact positively on patient outcomes. Keywords: adherence, atypical antipsychotics, adverse events
format	article
author	Peuskens J
author_facet	Peuskens J
author_sort	Peuskens J
title	The management of schizophrenia: focus on extended-release quetiapine fumarate
title_short	The management of schizophrenia: focus on extended-release quetiapine fumarate
title_full	The management of schizophrenia: focus on extended-release quetiapine fumarate
title_fullStr	The management of schizophrenia: focus on extended-release quetiapine fumarate
title_full_unstemmed	The management of schizophrenia: focus on extended-release quetiapine fumarate
title_sort	management of schizophrenia: focus on extended-release quetiapine fumarate
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/0a7a9e29149b401290c9eac1d3864aa3
work_keys_str_mv	AT peuskensj themanagementofschizophreniafocusonextendedreleasequetiapinefumarate AT peuskensj managementofschizophreniafocusonextendedreleasequetiapinefumarate
_version_	1718398524795650048

The management of schizophrenia: focus on extended-release quetiapine fumarate

Ejemplares similares